Inovio Pharmaceuticals, Inc.NASDAQ: INO

INOVIO Announces Pricing of $20.0 Million Public Offering

· Issued by Inovio Pharmaceuticals, Inc. via PR Newswire

Summary by 6ix AI

INOVIO Pharmaceuticals, a biotechnology company developing DNA medicines, priced an underwritten public offering on July 29, 2026 of 21,052,632 common shares with warrants to buy up to 42,105,264 more shares, at a combined $0.95 per share and accompanying warrant to purchase two shares.

Key details

  • The warrants have an exercise price of $1.10 per share of common stock.
  • Gross proceeds are expected to be approximately $20.0 million before underwriting discounts, commissions and offering expenses, excluding the underwriter's option and assuming no exercise of the warrants.
  • INOVIO granted the underwriter a 30-day option to buy up to 3,157,894 additional shares and/or warrants for up to 6,315,788 additional shares at the offering price, less underwriting discounts and commissions.
  • Piper Sandler is the sole manager, and all securities in the offering are being sold by INOVIO.
  • The shelf registration statement for the offering was filed with the US Securities and Exchange Commission on July 2, 2026 and declared effective on July 10, 2026. A shelf registration lets a company register securities in advance to sell later.

What’s still pending

  • The offering is expected to close on or about July 31, 2026, subject to customary closing conditions.

6ix AI wrote this summary from the release below and checked it against the release.

PLYMOUTH MEETING, Pa., July 29, 2026 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced the pricing of an underwritten public offering of 21,052,632 shares of its common stock and accompanying warrants to purchase up to 42,105,264 shares of its common stock (or pre-funded warrants in lieu thereof) with an exercise price of $1.10 per share of common stock, at a combined public offering price of $0.95 per share of common stock and accompanying warrant to purchase two shares of common stock. INOVIO also granted the underwriter an option for a period of 30 days to purchase up to 3,157,894 additional shares of the Company's common stock and/or warrants to purchase up to 6,315,788 additional shares of its common stock (or pre-funded warrants in lieu thereof) at the public offering price, less the underwriting discounts and commissions. All of the securities in the offering are being sold by INOVIO. The offering is expected to close on or about July 31, 2026, subject to the satisfaction of customary closing conditions.

The gross proceeds from the offering, before deducting the underwriting discounts and commissions and offering expenses payable by INOVIO, and excluding any exercise of the underwriter's option to purchase additional securities and assuming no exercise of the accompanying warrants, are expected to be approximately $20.0 million.

Piper Sandler is acting as sole manager for the offering.

A shelf registration statement relating to the shares of common stock and accompanying warrants offered in the offering described above was filed with the Securities and Exchange Commission ("SEC") on July 2, 2026 and declared effective by the SEC on July 10, 2026. The offering is being made only by means of a written prospectus and prospectus supplement that form a part of the registration statement. A preliminary prospectus supplement and accompanying prospectus relating to and describing the terms of the offering were filed with the SEC and are available on the SEC's website at www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus, when available, may also be obtained by contacting: Piper Sandler & Co., 350 North 5th Street, Suite 1000, Minneapolis, Minnesota 55401, Attention: Prospectus Department, by telephone at (800) 747-3924, or by e-mail at [email protected].

This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities being offered, nor shall there be any sale of the securities being offered in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About INOVIO

INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. INOVIO's technology optimizes the design and delivery of innovative DNA medicines that teach the body to manufacture its own disease-fighting tools.

Forward-Looking Statements

This release contains or may imply "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are not based on historical fact and include, but are not limited to, statements regarding the public offering of INOVIO's securities, including the timing of the closing of the offering, as well as the anticipated proceeds of the offering. Any forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties related to market conditions and satisfaction of customary closing conditions related to the proposed public offering. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled "Risk Factors" in INOVIO's Quarterly Report on Form 10-Q for the quarter ended March 31, 2026 and in other filings that INOVIO makes with the SEC from time to time. There can be no assurance that any of the forward-looking information provided herein will be proven accurate. These forward-looking statements speak only as of the date hereof and INOVIO undertakes no obligation to update forward-looking statements, and readers are cautioned not to place undue reliance on such forward-looking statements.

Contacts

Media: Jennie Willson (267) 429-8567 [email protected]
Investors: Peter Vozzo, ICR Healthcare, 443-213-0505 [email protected]

View original content to download multimedia:https://www.prnewswire.com/news-releases/inovio-announces-pricing-of-20-0-million-public-offering-302838434.html

SOURCE Inovio Pharmaceuticals, Inc.

View original source (PR Newswire)Inovio Pharmaceuticals, Inc. on 6ix

Story so far

Earlier from Inovio Pharmaceuticals

Later from Inovio Pharmaceuticals

All Inovio Pharmaceuticals news releases